Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Trimmed by GUARDCAP ASSET MANAGEMENT Ltd

GUARDCAP ASSET MANAGEMENT Ltd decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 11.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,400,163 shares of the life sciences company's stock after selling 324,655 shares during the quarter. Illumina comprises 5.2% of GUARDCAP ASSET MANAGEMENT Ltd's holdings, making the stock its 10th biggest position. GUARDCAP ASSET MANAGEMENT Ltd owned approximately 1.51% of Illumina worth $320,734,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Versant Capital Management Inc lifted its holdings in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after purchasing an additional 146 shares during the period. Golden State Wealth Management LLC purchased a new position in Illumina during the 4th quarter worth approximately $32,000. Assetmark Inc. lifted its stake in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after acquiring an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Illumina in the 4th quarter valued at $45,000. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of Illumina in the fourth quarter worth $48,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ILMN shares. Hsbc Global Res downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Canaccord Genuity Group lowered their target price on Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a research note on Tuesday, March 11th. TD Cowen cut Illumina from a "buy" rating to a "hold" rating and reduced their price target for the company from $177.00 to $140.00 in a research report on Friday, February 7th. HSBC downgraded Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target for the company. in a report on Friday, February 28th. Finally, Robert W. Baird cut their target price on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Illumina has a consensus rating of "Moderate Buy" and an average price target of $140.90.

Remove Ads

Illumina Price Performance

NASDAQ:ILMN traded down $0.55 during trading hours on Thursday, hitting $82.28. 1,812,730 shares of the stock were exchanged, compared to its average volume of 2,110,750. The firm's fifty day moving average price is $103.93 and its 200 day moving average price is $127.08. Illumina, Inc. has a 52-week low of $80.18 and a 52-week high of $156.66. The company has a market cap of $13.03 billion, a P/E ratio of -10.71, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.